Key facts
- Nacuity Pharmaceuticals’s last known valuation is $52.0M (Jun 2022).
- It has raised $40.6M across 4 recorded rounds; the latest was Early Stage VC ($8.4M) in Dec 2025.
- Notable investors include Foundation Fighting Blindness-National Neurovision Research Institute, HSC Next, Johns Hopkins Technology Ventures, Retinal Degeneration Fund, Tarnagulla Ventures.
- Nacuity Pharmaceuticals has filed 5 Form Ds with the SEC since 2016, most recently Jan 2022 ($11.6M sold to 144 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 4 rounds
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for Nacuity Pharmaceuticals
Funding rounds
4 roundsAbout Nacuity Pharmaceuticals
Operator of a biotechnology company intended to offer treatments for retinitis pigmentosa and other ophthalmological disorders. The company offers drug candidates focused on treating ocular oxidative stress and other ocular diseases, enabling healthcare professionals to help and treat patients suffering from such disorders.
- Sector
- Healthcare
- HQ
- Fort Worth, TX, United States
- Founded
- 2017
- Employees
- 6
- Website
- nacuity.com/
- Ownership
- Privately Held (backing)
Nacuity Pharmaceuticals doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Nacuity Pharmaceuticals shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Nacuity Pharmaceuticals in its N-PORT filings yet. We sweep new filings monthly.